GILEAD

EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024

Retrieved on: 
星期五, 五月 31, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Merck & Co., Patient, Progression-free survival, Diarrhea, Doctor of Philosophy, Survival, Pembrolizumab, Neutropenia, Docetaxel, Lung cancer, PFS, Histology, Safety, NSCLC, ADC, MD, Gilead Sciences, Science, Death, Abstract, Neoplasm, Incidence, ASCO, Merck, Journal, Hospital, OS, Fatigue, Society, Aes, Standard of care, Annual general meeting, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • The company previously announced that the study did not meet the primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
  • “Treating patients with metastatic NSCLC who have progressed on available treatments continues to be a challenge.
  • Longer-term results from Cohort A of the Phase 2 EVOKE-02 study of Trodelvy in combination with KEYTRUDA® (pembrolizumab) in first-line metastatic PD-L1 ≥50% NSCLC will also be presented in a poster session (Abstract #8592) on June 3, 2024.

Gilead Provides Update on Phase 3 TROPiCS-04 Study

Retrieved on: 
星期四, 五月 30, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Patient, Progression-free survival, Survival, TPC, UC, Bladder cancer, G-CSF, Diagnosis, FDA, PFS, Breast cancer, ADC, Ageing, ITT, Death, Metastasis, OS, Physician, MUC, Infection, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the confirmatory Phase 3 TROPiCS-04 study in locally advanced or metastatic urothelial cancer (mUC).
  • The study did not meet the primary endpoint of overall survival (OS) in the intention-to-treat (ITT) population.
  • Gilead is continuing to analyze the data and will discuss the results and next steps with the FDA.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials, including the TROPiCS-04 study.

Clarametyx Biosciences Appoints Renowned Experts to Augment Strategic and Scientific Advisory Boards

Retrieved on: 
星期二, 五月 28, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, Biogen, Shionogi, Annamalai University, General partnership, Genentech, Biochemistry, Sarepta Therapeutics, Takeda Oncology, Biofilm, Flagship Pioneering, Palani, University, Therapy, Virginia Commonwealth University, Infection, MBA, Biophysics, MD, Takeda Pharmaceutical Company, Executive, Management

Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.

Key Points: 
  • Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences.
  • His early career included leadership positions at Millennium Pharmaceuticals (acquired by Takeda), Biogen, Nexstar Pharmaceuticals (acquired by Gilead), and Par Pharmaceuticals.
  • He is currently a Managing Partner and Co-Founder of Trekk Venture Partners and serves on multiple public and private company boards.
  • Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego.

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Retrieved on: 
星期二, 五月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Infectious Diseases, Clinical Trials, Patient, Infection, Prognosis, WEE1, HER2, Clinical trial, University, Diagnosis, AACR, Safety, Breast cancer, Sacituzumab govitecan, ADC, Gilead Sciences, HR, Breast, Metastasis, Cell, Mortality, IST, PR, University of Bristol, TNBC, Pharmaceutical industry

Hormone receptor-positive (HR+)/HER2- is the most common type of breast cancer and it accounts for 70% of all breast cancers.

Key Points: 
  • Hormone receptor-positive (HR+)/HER2- is the most common type of breast cancer and it accounts for 70% of all breast cancers.
  • “It’s great to see companies like Debiopharm that are open to investigating novel combination strategies to support breast cancer patients.
  • “We are honored to develop this Investigator Sponsor Trial (IST) in collaboration with Debiopharm and Gilead to explore new approaches to breast cancer treatment.
  • The foundations for this clinical trial were set by the promising preclinical data suggesting an existing synergy between Debiopharm’s Debio 0123 and Gilead’s sacituzumab govitecan.

Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies Against Novel Targets and Target Pairs

Retrieved on: 
星期二, 五月 28, 2024
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Genomics, Antigen, Patient, Algorithm, Lung cancer, Drug development, NSCLC, Adenocarcinoma, Gilead Sciences, Triple-negative breast cancer, ATLAS, Cartography, TNBC, Pharmaceutical industry

Under the multi-year collaboration, Cartography’s proprietary computational and genomics platform will be utilized to discover and validate novel tumor-selective target antigens and pairs of antigens.

Key Points: 
  • Under the multi-year collaboration, Cartography’s proprietary computational and genomics platform will be utilized to discover and validate novel tumor-selective target antigens and pairs of antigens.
  • Gilead can opt in on multiple targets identified through this collaboration and will undertake all further research, development, and commercialization of programs against those targets.
  • “We are excited to partner with Gilead to identify novel and compelling antigen targets using our ATLAS and SUMMIT platforms,” said Kevin Parker, Ph.D., CEO of Cartography Biosciences.
  • Cartography is also eligible to receive development, regulatory and commercial milestones, and tiered royalties on net sales for Gilead programs against each optioned target.

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Retrieved on: 
星期三, 五月 22, 2024
Doctor of Philosophy, EASL, Treatment, Genital herpes, Viral, Poster, Safety, SAN, Assembly, Gilead Sciences, HSV, HDV, Cirrhosis, Hepatitis D, Viral hepatitis, Injection, Abstract, Therapy, Biotechnology, Standard of care, Vaccine

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the company will present data from its herpes simplex virus (HSV) and hepatitis D virus (HDV) pipeline programs at upcoming medical congresses. Assembly Bio’s abstracts for ABI-5366 and ABI-1179 have been accepted for one oral and two poster presentations at the International Herpesvirus Workshop, taking place in Portland, Ore., July 13-17, 2024. An abstract for ABI-6250 has been accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 taking place in Milan, Italy, June 5-8, 2024.

Key Points: 
  • Assembly Bio’s abstracts for ABI-5366 and ABI-1179 have been accepted for one oral and two poster presentations at the International Herpesvirus Workshop, taking place in Portland, Ore., July 13-17, 2024.
  • An abstract for ABI-6250 has been accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress™ 2024 taking place in Milan, Italy, June 5-8, 2024.
  • At the International Herpesvirus Workshop, Assembly Bio will present data describing the preclinical profile of ABI-5366, a long-acting helicase-primase inhibitor candidate in development for the treatment of recurrent genital herpes.
  • “We’re excited to present data from both of these potent, long-acting HSV helicase-primase inhibitors at the International Herpesvirus Workshop,” said William Delaney, PhD, chief scientific officer of Assembly Bio.

Galapagos creates new subscription right plans

Retrieved on: 
星期四, 五月 16, 2024
FC Volna Pinsk, Exercise, Therapy, Euronext, RMV, Brussels Stock Exchange, Holding company

On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital.

Key Points: 
  • On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2024 ROW”, primarily intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital.
  • Under these subscription right plans, 1,614,000 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans.
  • The subscription rights under Subscription Right Plan 2024 RMV and Subscription Right Plan 2024 ROW vest and become exercisable in instalments: with 25% of each grant being exercisable as of 1 January 2026, 25% as of 1 January 2027 and 50% as of 1 January 2028.
  • This excludes the 1,614,000 subscription rights of Subscription Right Plan 2024 BE, Subscription Right Plan 2024 RMV and Subscription Right Plan 2024 ROW, which were created subject to acceptance.

Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024

Retrieved on: 
星期三, 五月 22, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Hospitals, Clinical Trials, Hepatitis C, Risk, Medicaid, FDA, Senior, PBC, Congress, HDV, Itch, HCV, Woman, Cirrhosis, Abstract (summary), Bulevirtide, European Economic Area, Hepatitis, Liver disease, Ascending cholangitis, HBV, MD, Civil service commission, European Commission, Primary biliary cholangitis, Ursodeoxycholic acid, Gross metropolitan product, Food, Education, Disease, Safety, Gilead Sciences, ULN, Incidence, Policy, Alkaline phosphatase, Viral hepatitis, WHO, Liver cancer, Liver failure, Patient, EASL, Diagnosis, Abstract, UDCA, Fatigue, Quality of life, ALP, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy.
  • “These data underline Gilead’s commitment to drive life-changing science and create healthier futures for people living with liver disease.
  • “The breadth of our data being presented across viral and inflammatory liver diseases, speaks to our commitment to driving positive change at every step of a person’s journey.
  • Further highlighting Gilead as a leader in HDV research, a sub-analysis of the MYR204 study (OS-122) evaluating intrahepatic virological outcomes 24 Weeks off-treatment will be presented.

Royalty Pharma Reports First Quarter 2024 Results

Retrieved on: 
星期四, 五月 9, 2024
FDA, Ulcerative colitis, KarXT, Food, MorphoSys, European Commission, Marketing, New Drug Application, Cystic fibrosis, PDSS, PANSS, Tourette syndrome, Lupus, Docetaxel, Roche, Schizophrenia, Novartis, ADP, Pfizer, Incidence, Bristol Myers Squibb, Patient, Neurology, Acquisition, Sacituzumab govitecan, Olanzapine, Civil service commission, Multiple sclerosis, Positive, Vertex, Sanofi, Teva Pharmaceuticals, Astellas Pharma, European Medicines Agency, Lung cancer, Pharmaceutical industry

During 2024, Royalty Pharma announced new transactions of up to $619 million.

Key Points: 
  • During 2024, Royalty Pharma announced new transactions of up to $619 million.
  • In January 2024, Royalty Pharma acquired a royalty interest in ecopipam for an upfront payment of $49 million and up to $44 million in milestone payments contingent on the achievement of certain regulatory milestones.
  • In May 2024, Royalty Pharma announced a transaction to acquire royalties and milestones on frexalimab owned by ImmuNext for approximately $525 million in cash including estimated transaction costs.
  • Royalty Pharma has provided guidance for full year 2024, excluding transactions and borrowings announced after the date of this release, as follows:

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Retrieved on: 
星期四, 五月 9, 2024
FDA, Probability, Gilead Sciences, Food, Pembrolizumab, OPSCC, Partnership, IND, Roche, ASCO, Arenavirus, PRIME, Patient, EMA, Lung, Hepatitis B, HIV, Clinical trial, Annual general meeting, Food and Drug Administration, HBV, Pharmaceutical industry

The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.

Key Points: 
  • The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.
  • Effective April 25, 2024, HOOKIPA regained full control of the associated intellectual property portfolio and has full collaboration and licensing rights for this program.
  • HOOKIPA received FDA clearance of its IND application in the fourth quarter of 2023 and expects to initiate a Phase 1 clinical trial of HB-500 in people with HIV in the second quarter of 2024.
  • On January 29, 2024, HOOKIPA provided an update on its business priorities and oncology partnership programs.